ANGPT2 and wet macular degeneration: Novel therapeutics are under study, including anti-Ang-2/anti-VEGFA bispecific antibody Faricimab (RG7716, Roche)36, recently approved in the US for treatment of DME and wet age-related macular degeneration (AMD)37.